Month: September 2021

LOS ANGELES, Sept. 21, 2021 (GLOBE NEWSWIRE) — NASA has selected Aerojet Rocketdyne to build the Orion Main Engine (OME), the primary propulsion element for NASA’s Orion spacecraft that will be used to explore deep space. Under the contract, which runs through 2032, Aerojet Rocketdyne will deliver up to 20 new OME engines for use on future Artemis missions beginning with Artemis VII, or to support other NASA-sponsored, deep space exploration missions. The OME is a 6,000 pound-thrust bipropellant engine that is mounted on Orion’s European Service module and will be built at Aerojet Rocketdyne’s Los Angeles, California, and Redmond, Washington, facilities. The engine is used for major maneuvers in space, such as entering and departing lunar orbit, and in some mission abort scenarios. The first six Orion missions will use refurbished...

New York, NY, Sept. 21, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — AdvanceTC Ltd (NSX:A88)(OTCQB:ATCLF) (‘AdvanceTC’ or the ‘Company’) is pleased to announce that it received orders for 4,000 phones. The orders are comprised of 2,000 units of Xplore X7U DMR and 2,000 units of Xplore X7U DMR with Satellite Messaging. The Company anticipates the shipment of these 4,000 units to reach Regional Marketing Arms (RMA’s) customers within December 2021. AdvanceTC has been requested to increase its production capacity and is glad to inform that it will be able to double its production in the month of December 2021 to 8,000 units to meet the anticipated demand from the RMA’s and their customers. The Company is able to continue to further increase its production capacity in coming months as the demand grows. Following the successful...

The Board of Directors Unanimously Recommends Nabis Shareholders and Noteholders to Vote in Favour of the Arrangement and Related Transactions VANCOUVER, British Columbia, Sept. 21, 2021 (GLOBE NEWSWIRE) — Nabis Holdings Inc. (CSE: NAB) (OTC: NABIF) (FRA: A2PL) (“Nabis” or the “Company”) announces that it is seeking court permission to issue a notice of application on the Ontario Superior Court of Justice (Commercial List) (the “Application”) against Caravel CAD Fund Ltd (“Caravel”). In the Application, Nabis will seek an order enforcing the support agreement between Caravel and the Company dated July 2, 2021 (“Support Agreement”) in which Caravel agreed to vote in favour of the proposed plan of arrangement (“Arrangement”). In the alternative, Nabis will seek damages in the amount of approximately $12 million, being the approximate...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Sept. 21, 2021 (GLOBE NEWSWIRE) — Sulliden Mining Capital Inc. (TSX: SMC) (“Sulliden” or the “Company”) announces a non-brokered private placement financing of up to 7,500,000 units of the Company (“Units”) at a price of $0.06 per Unit for gross proceeds to the Company of up to $450,000 (the “Offering”). Each Unit will consist of one common share of the Company and one common share purchase warrant (a “Warrant”). Each Warrant will entitle the holder thereof to acquire one common share of the Company at a price of $0.25 for a period of five years following the closing date of the Offering. All securities issued in connection with the Offering will be subject to a statutory hold period of four-months and one day. Completion of...

BOSTON, Sept. 21, 2021 (GLOBE NEWSWIRE) — In a release issued on Wednesday, September 21 by Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), please note that the symbol ▼ was erroneously omitted from the headline. The corrected release follows: Rhythm Pharmaceuticals Announces Marketing Authorisation of ▼IMCIVREE® (setmelanotide) in Great Britain – IMCIVREE is indicated for treatment of obesity and control of hunger associated with genetically confirmed loss-of-function biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children six years of age and above – – First-ever authorised treatment option in Great Britain (England, Scotland and Wales) for these rare genetic diseases of obesity – – IMCIVREE selected as ‘highly specialised technology’ and scheduled...

Conference Call Rescheduled for Wednesday, September 22 at 10:00 a.m. ET/7:00 a.m. PT RICHLAND, Wash., Sept. 21, 2021 (GLOBE NEWSWIRE) — Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in brachytherapy powering expanding treatment options throughout the body, will host a rescheduled conference call to discuss its financial results for the fourth quarter and fiscal year ended June 30, 2021 on Wednesday, September 22, 2021, at 10:00 a.m. Eastern Time/7:00 a.m. Pacific. The rescheduled conference call was necessitated by the conference bridge provider’s technical failure. The Company has already issued a press release announcing its financial results for the fourth quarter and fiscal year ended June 30, 2021. The press release was issued after the close of the U.S. stock markets on September 21, 2021. To...

MCLEAN, Va., Sept. 21, 2021 (GLOBE NEWSWIRE) — Freddie Mac (OTCQB: FMCC) recently priced a new offering of Multifamily WI K-Deal Certificates (WI Certificates), which are initially backed by cash assets that will be used to purchase the A-M class of a to-be-issued reference K-Deal. Once the reference K-Deal class is issued and purchased by the WI trust, the WI Certificates will be indirectly backed by a pool of fixed-rate multifamily mortgages with predominantly 10-year terms. The company expects to issue approximately $170 million in WI Certificates (Series WI-K132), which are expected to settle on or about September 28, 2021. “Today we are pleased to announce the successful pricing of our inaugural WI K-Deal offering, WI-K132,” said Robert Koontz, senior vice president of Capital Markets for Freddie Mac Multifamily. “The WI K-Deal...

– IMCIVREE is indicated for treatment of obesity and control of hunger associated with genetically confirmed loss-of-function biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children six years of age and above – – First-ever authorised treatment option in Great Britain (England, Scotland and Wales) for these rare genetic diseases of obesity – – IMCIVREE selected as ‘highly specialised technology’ and scheduled for review by National Institute for Health and Care Excellence (NICE) in December 2021 – BOSTON, Sept. 21, 2021 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that Great Britain’s...